Acetyl-CoA carboxylase (ACC) is a crucial metabolic enzyme that plays a vital 
role in obesity-induced type 2 diabetes and fatty acid metabolism. To identify 
dual inhibitors of Acetyl-CoA carboxylase1 and Acetyl-CoA carboxylase2, a 
pharmacophore modelling approach has been employed. The best HypoGen 
pharmacophore model for ACC2 inhibitors (Hypo1_ACC2) consists of one hydrogen 
bond acceptor, one hydrophobic aliphatic and one hydrophobic aromatic feature, 
whereas the best pharmacophore (Hypo1_ACC1) for ACC1 consists of one additional 
hydrogen-bond donor (HBD) features. The best pharmacophore hypotheses were 
validated by various methods such as test set, decoy set and Cat-Scramble 
methodology. The validated pharmacophore models were used to screen several 
small-molecule databases, including Specs, NCI, ChemDiv and Natural product 
databases to identify the potential dual ACC inhibitors. The virtual hits were 
then subjected to several filters such as estimated [Formula: see text] value, 
quantitative estimation of drug-likeness and molecular docking analysis. 
Finally, three novel compounds with diverse scaffolds were selected as potential 
starting points for the design of novel dual ACC inhibitors.